{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:56:20Z","timestamp":1791608180301,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.oret.2025.05.025","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T19:42:52Z","timestamp":1748374972000},"page":"1187-1196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment Patterns and Long-term Outcomes with Anti\u2013VEGF Therapy for Retinal Vein Occlusion"],"prefix":"10.1016","volume":"9","author":[{"given":"Michael","family":"Ip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasha","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Fekrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9016-3481","authenticated-orcid":false,"given":"Kara","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-575X","authenticated-orcid":false,"given":"Nick","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Arrisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9312-9924","authenticated-orcid":false,"given":"Liliana P.","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7933-4617","authenticated-orcid":false,"given":"Matthew","family":"Fenech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria C.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.05.025_bib1","doi-asserted-by":"crossref","first-page":"P288","DOI":"10.1016\/j.ophtha.2019.09.029","article-title":"Retinal Vein Occlusions Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.025_bib2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41433-022-02007-4","article-title":"Retinal vein occlusion (RVO) guideline: executive summary","volume":"36","author":"Nicholson","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.05.025_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000502041","article-title":"Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA)","volume":"242","author":"Schmidt-Erfurth","year":"2019","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2025.05.025_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.025_bib5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ajo.2022.04.001","article-title":"Month 60 outcomes after treatment initiation with anti-vascular endothelial growth factor therapy for macular edema due to central retinal or hemiretinal vein occlusion","volume":"240","author":"Scott","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib6","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41433-021-01620-z","article-title":"Long-term outcomes of anti-VEGF treatment of retinal vein occlusion","volume":"36","author":"Spooner","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.05.025_bib7","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.4103\/ijo.IJO_1330_22","article-title":"Long-term real-world outcomes in retinal vein occlusions: how close are we to the trials?","volume":"70","author":"Shah","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00417-020-04932-0","article-title":"Macular edema secondary to retinal vein occlusion in a real-life setting: a multicenter, nationwide, 3-year follow-up study","volume":"259","author":"Costa","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/bjophthalmol-2020-317337","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1159\/000530294","article-title":"Real-world outcomes of ranibizumab treatment in French patients with visual impairment due to macular edema secondary to retinal vein occlusion: 24-month results from the BOREAL-RVO study","volume":"66","author":"Glacet-Bernard","year":"2023","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.oret.2025.05.025_bib11","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1177\/11206721221085870","article-title":"Long-term outcomes of anti-VEGF treatment of macular oedema due to retinal vein occlusions","volume":"32","author":"Corazza","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/2474126421989225","article-title":"Antivascular endothelial growth factor dosing frequency and visual outcomes in macular edema following central retinal vein occlusion","volume":"5","author":"Modi","year":"2021","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.oret.2025.05.025_bib13","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/s41433-023-02527-7","article-title":"Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion","volume":"37","author":"Modi","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.05.025_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234739","article-title":"Real-world outcomes with ranibizumab in branch retinal vein occlusion: the prospective, global, LUMINOUS study","volume":"15","author":"Pearce","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2025.05.025_bib15","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/s41433-021-01702-y","article-title":"Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study","volume":"36","author":"Lotery","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.05.025_bib16","first-page":"353","article-title":"Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV","volume":"101","author":"Wecker","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib17","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2147\/OPTH.S209253","article-title":"Real-world data: ranibizumab treatment for retinal vein occlusion in the OCEAN study","volume":"13","author":"Callizo","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib18","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.oret.2022.03.021","article-title":"Longer-term anti-VEGF therapy outcomes in neovascular age-related macular degeneration, diabetic macular edema, and vein occlusion-related macular edema: clinical outcomes in 130 247 eyes","volume":"6","author":"Ciulla","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.05.025_bib19","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2147\/OPTH.S100168","article-title":"Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion","volume":"10","author":"Sivaprasad","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12886-023-03018-9","article-title":"Analyze of factors and prognosis of eyes lost to follow-up in retinal vein occlusive disease patients receiving anti-vascular endothelial growth factor therapy","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib21","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.025_bib22","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.025_bib23","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","article-title":"Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study","volume":"158","author":"Ogura","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/OPTH.S163859","article-title":"Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)","volume":"12","author":"Jumper","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib25","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.05.025_bib26","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.025_bib27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.025_bib28","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.025_bib29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","article-title":"Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study","volume":"155","author":"Brown","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","article-title":"VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","article-title":"Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.025_bib32","doi-asserted-by":"crossref","first-page":"756","DOI":"10.5301\/ejo.5000943","article-title":"Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal","volume":"27","author":"Vaz-Pereira","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib33","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0161-6420(95)30849-4","article-title":"Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report","volume":"102","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.025_bib34","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.025_bib35","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.025_bib36","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/bjophthalmol-2016-308727","article-title":"Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice","volume":"101","author":"Wai","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.025_bib37","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jamaophthalmol.2017.1141","article-title":"Baseline factors associated with 6-month visual acuity and retinal thickness outcomes in patients with macular edema secondary to central retinal vein occlusion or hemiretinal vein occlusion: SCORE2 study report 4","volume":"135","author":"Scott","year":"2017","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025002519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025002519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:40:05Z","timestamp":1764747605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025002519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2468653025002519"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.05.025","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns and Long-term Outcomes with Anti\u2013VEGF Therapy for Retinal Vein Occlusion","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}